Innovative Drug Delivery Systems and Disease Models for Pulmonary Fibrosis
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".
Deadline for manuscript submissions: 15 August 2024 | Viewed by 212
Special Issue Editors
Interests: controlled release; solid state properties; organic and inorganic nano- microparticles; inhaled dry powders; drug physical modification; cell microencapsulation and engineering
Special Issues, Collections and Topics in MDPI journals
Interests: silicosis; occupational lung diseases; particulate matter exposure; fibrosis
Special Issue Information
Dear Colleagues,
Pulmonary fibrosis is a devastating and irreversible lung disease of unknown aetiology. Treatment options are available, but they are limited to managing symptoms and slowing down the disease until respiratory failure occurs. While pirfenidone and nintedanib have been shown to slow down the progression of the disease, they may have unwanted side effects. This highlights the importance of developing novel drug delivery systems to increase drug efficacy while reducing the risk of potential toxic side effects. Novel disease models that mimic the 3D physiological environment can contribute to a better understanding of how pulmonary fibrosis develops and progresses.
This Special Issue serves to highlight the current advancements in novel drug delivery systems and disease models for pulmonary fibrosis. We welcome all articles that are related to drug delivery systems and disease models used to study (fibrotic) lung disease.
Dr. Stefano Giovagnoli
Dr. Anna Yeung
Dr. Kaj Blokland
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- controlled drug release
- treatment targets
- nanoparticles
- extracellular vesicles
- aerosols
- organoids
- 3D culturing
- lung-on-a-chip
